![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ViiV to License Its HIV Prevention Drug to MPP
ViiV to License Its HIV Prevention Drug to MPP
ViiV Healthcare has agreed to license patents covering Apretude (cabotegravir), its long-acting human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) drug, to the Medicines Patent Pool (MPP) to increase access to medicines in low- and middle-income countries.
The United Nations-backed MPP said it will now negotiate with ViiV to secure a license to enable the development of generic versions of Apretude. MPP believes Apretude could potentially be “a very important drug” in the battle against HIV because of its long-acting nature.
The company said that until a generic version of the drug is available, ViiV will supply Apretude to public programs in “low-income, least-developed and all sub-Saharan African countries” at what it calls a “nonprofit price.” Apretude, which was FDA-approved in December 2021, costs $3,700 per dose.
Upcoming Events
-
21Oct